VEGFC
Vascular endothelial growth factor C
As of the edition of 20 October 2026, VEGFC (vascular endothelial growth factor C, UniProt P49767) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49767
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 6
- Disease areas
- Eye; Heart and blood vessels; Cancer; Hormones; Inherited and neonatal; Nutrition and metabolism
- Registered trials of its drugs
- 38
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Conbercept | Marketed | Phase 4 | none listed |
| Sozinibercept | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Opthea | Route A |
| Chengdu Kanghong Biotech | Route B |
The other 0 companies at VEGFC
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at VEGFC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.